Search Within

Stuart Lichtman

  1. "Hematologic Malignancies, Division of"
Formats
  1. Journal Article (13)
  2. Meeting Abstract (11)
Groups
  1. Department of Medicine (24)
  2. Gynecologic Medicine Service (24)
  3. Hematologic Malignancies, Division of (24)
  4. Solid Tumor Oncology Division (24)
  5. GDMT, Medicine (20)
  6. Gynecology Disease Management Team (20)

More Groups

People
  1. William Tew (16)
  2. Roisin O'Cearbhaill (14)
  3. Carol Aghajanian (13)
  4. Jason Konner (10)
  5. Qin Zhou (10)
  6. Alexia Iasonos (9)

More People

Years
  1. 2024 (1)
  2. 2023 (2)
  3. 2022 (3)
  4. 2021 (1)
  5. 2020 (1)
  6. 2019 (2)

More Years

Publications
  1. Journal of Clinical Oncology (9)
  2. Gynecologic Oncology (4)
  3. Journal of Geriatric Oncology (3)
  4. Journal of the American Geriatrics Society (3)
  5. Annals of Oncology (1)
  6. Blood (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (10)
  2. Elsevier Inc. (7)
  3. Wiley Blackwell (3)
  4. American Association for Cancer Research (1)
  5. American Society of Hematology (1)
  6. Nature Publishing Group (1)

More Publishers

Results (24)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: A phase 2 trial with biomarker analyses
    Journal Article

    Friedman, C. F.; Manning-Geist, B. L.; Zhou, Q.; Soumerai, T.; Holland, A.; Da Cruz Paula, A.; Green, H.; Ozsoy, M. A.; Iasonos, A.; Hollmann, T.; more...
    Nature Medicine (2024)

    Fulltext@MSK | Save
  • Carboplatin dosing in the treatment of ovarian cancer: An NRG Oncology group study
    Journal Article

    Praiss, A. M.; Miller, A.; Smith, J.; Lichtman, S. M.; Bookman, M.; Aghajanian, C.; Sabbatini, P.; Backes, F.; Cohn, D. E.; Argenta, P.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study
    Journal Article

    Rubinstein, M. M.; Doria, E. R.; Konner, J.; Lichtman, S.; Zhou, Q.; Iasonos, A.; Sarasohn, D.; Troso-Sandoval, T.; Friedman, C.; O'Cearbhaill, R.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • A phase II trial of IDO-inhibitor, BMS-986205 (IDO), and PD-1 inhibitor, nivolumab (NIVO), in recurrent or persistent endometrial cancer (EC; CA017-056)
    Meeting Abstract

    Kyi, C.; Rubinstein, M. M.; Shah, P.; Zhou, Q.; Iasonos, A.; Liu, Y.; Ramirez, L.; Paroder, V.; Green, A.; Friedman, C. F.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Dysfunctional CD8+T cells in the tumor microenvironment are associated with response to nivolumab in mismatch repair deficient (dMMR) or hypermutated ovarian (OVCA) or endometrial cancer (EC)
    Meeting Abstract

    Friedman, C. F.; Zhou, Q.; Iasonos, A.; Holland, A.; Ramirez, L.; Grisham, R. N.; Guo, R.; Lichtman, S. M.; Kyi, C.; Makker, V.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer
    Journal Article

    Manning-Geist, B. L.; Gordhandas, S. B.; Giri, D. D.; Iasonos, A.; Zhou, Q.; Girshman, J.; O'Cearbhaill, R. E.; Zamarin, D.; Lichtman, S. M.; Sabbatini, P. J.; more...
    Gynecologic Oncology (2022)

    Fulltext@MSK | Save
  • Secondary cytoreduction and carboplatin hyperthermic intraperitoneal chemotherapy for platinum-sensitive recurrent ovarian cancer: An MSK Team Ovary phase II study
    Journal Article

    Zivanovic, O.; Chi, D. S.; Zhou, Q.; Iasonos, A.; Konner, J. A.; Makker, V.; Grisham, R. N.; Brown, A. K.; Nerenstone, S.; Diaz, J. P.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A randomized phase II trial of secondary cytoreductive surgery (SCS) plus /- carboplatin hyperthermic intraperitoneal chemotherapy (HIPEC) in patients (pts) with recurrent platinum-sensitive ovarian cancer (EOC)
    Meeting Abstract

    Zivanovic, O.; Chi, D.; Zhou, Q.; Iasonos, A.; Makker, V.; Grisham, R. N.; Konner, J. A.; Diaz, J. P.; Brown, A. K.; Langstraat, C. L.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase 2 study of TPIV200/ huFR-1 (a multi-epitope folate receptor alpha vaccine) in combination with durvalumab in patients with platinum resistant ovarian cancer
    Meeting Abstract

    Zamarin, D.; Yeku, O.; O'Cearbhaill, R. E.; Cadoo, K. A.; Gallagher, J.; Kravetz, S.; McDonnell, A.; Troso-Sandoval, T.; Sabbatini, P.; Lichtman, S.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • A phase II trial of durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial carcinoma and endometrial carcinosarcoma
    Meeting Abstract

    Rubinstein, M. M.; Caird, I.; Zhou, Q.; Iasonos, A.; Friedman, C. F.; Cadoo, K. A.; Konner, J. A.; O'Cearbhaill, R. E.; Tew, W. P.; Zamarin, D.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save